Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, et al. Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematopathol. 2013;53:57–61.

Article  Google Scholar 

Takai K, Nikkuni K, Shibuya H, Hashidate H. [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]. Rinsho Ketsueki. 2010;51:320–5.

PubMed  Google Scholar 

Abdo L. First European case of TAFRO syndrome associated with Sjogren disease. Am J Intern Med. 2014;2:102–5.

Google Scholar 

Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, et al. Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol. 2015;4:3.

Article  PubMed  PubMed Central  Google Scholar 

Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220–6.

Article  PubMed  CAS  Google Scholar 

Masaki Y, Ueda Y, Yanagisawa H, Arita K, Sakai T, Yamada K, et al. Tafro syndrome: a disease requiring immediate medical attention. Intern Med. 2023;62:27–32.

Article  PubMed  CAS  Google Scholar 

Nishimura Y, Fajgenbaum DC, Pierson SK, Iwaki N, Nishikori A, Kawano M, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021;96:1241–52.

Article  PubMed  PubMed Central  Google Scholar 

Fujimoto S, Kawabata H, Sakai T, Yanagisawa H, Nishikori M, Nara K, et al. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol. 2021;113:73–80.

Article  PubMed  CAS  Google Scholar 

Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, et al. Successful treatment of a patient with multicentric Castleman’s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med. 2013;52:1503–7.

Article  PubMed  Google Scholar 

van Rhee F, Wong RS, Munshi N, Rossi J-F, Ke X-Y, Fosså A, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15:966–74.

Article  PubMed  Google Scholar 

Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, et al. Atypical hyaline vascular-type castleman’s disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematopathol. 2013;53:87–93.

Article  Google Scholar 

Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M, Ota Y. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A : a case report. J Clin Exp Hematopathol. 2013;53:95–9.

Article  Google Scholar 

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382:1800–10.

Article  PubMed  Google Scholar 

Killian M, Viel S, Chalayer E, Forest F, Grange S, Bonnefoy P-B, et al. JAK1/2 inhibition in severe TAFRO syndrome: a case report. Ann Intern Med. 2021;174:719–21.

Article  PubMed  Google Scholar 

Lust H, Gong S, Remiker A, Rossoff J. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: a pediatric case series. Pediatr Blood Cancer. 2021;68:e29261.

Article  PubMed  CAS  Google Scholar 

Kakutani T, Nunokawa T, Chinen N, Tamai Y. Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: a case report. Medicine (Baltimore). 2022;101:e32200.

Article  PubMed  Google Scholar 

Gao Y-H, Duan M-H, Li J, Zhang L. Ruxolitinib for the treatment of refractory idiopathic multicentric Castleman disease: a case report. Turk J Hematol. 2024;41:61–3.

Article  Google Scholar 

Kakutani T, Kamada R, Tamai Y. Pathophysiology, treatment, and prognosis of thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly (TAFRO) syndrome: a review. Curr Issues Mol Biol. 2024;46:11255–69.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

Article  PubMed  CAS  Google Scholar 

Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, et al. 2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111:155–8.

Article  PubMed  Google Scholar 

Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:686–92.

Article  PubMed  CAS  Google Scholar 

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132:2115–24.

Article  PubMed  PubMed Central  Google Scholar 

Pierson SK, Shenoy S, Oromendia AB, Gorzewski AM, Langan Pai R-A, Nabel CS, et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021;5:3445–56.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pai R-AL, Japp AS, Gonzalez M, Rasheed RF, Okumura M, Arenas D, et al. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight. 2020;5:e135031.

Article  PubMed  PubMed Central  Google Scholar 

Simons M, Apor E, Butera JN, Treaba DO. TAFRO syndrome associated with EBV and successful triple therapy treatment: case report and review of the literature. Case Rep Hematol. 2016;2016:4703608.

PubMed  PubMed Central  Google Scholar 

Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, et al. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016;101:660–71.

Article  PubMed  PubMed Central  Google Scholar 

Liu J, Wang F, Luo F. The role of JAK/STAT pathway in fibrotic diseases: molecular and cellular mechanisms. Biomolecules. 2023. https://doi.org/10.3390/biom13010119.

Article  PubMed  PubMed Central  Google Scholar 

Okamoto A, Yanada M, Miura H, Inaguma Y, Tokuda M, Morishima S, et al. Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma. Cancer Sci. 2015;106:1576–81.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Song Y, Wang J, Wang Y, Wang Z. Ruxolitinib in patients with chronic active Epstein-Barr virus infection: a retrospective, single-center study. Front Pharmacol. 2021;12:710400.

Article  PubMed  PubMed Central  Google Scholar